Oxford BioMedica plc · LSE:OXB

Oxford BioMedica — FY2012 Earnings Presentation

20 slides from Oxford BioMedica's earnings presentation, Feb 27, 2013

  1. Slide 1: Oxford BioMedica 2012 preliminary results

    Oxford BioMedica 2012 preliminary results 27 February 2013 © Oxford BioMedica 2013, all rights reserved

  2. Slide 2: Forward-looking statements

    Forward-looking statements This Cohortpresentation does 2 Dose not constituteAdministration an offer to sell or 3amonths solicitation (UPDRS) of offers to (UPDRS) 6 months buy Ordinary Shares 1 year (UPDRS) (the 2 years (UPDRS) “Securities”). 1, n=3 Although 1x reasonable care has been takenMean Ori

  3. Slide 3: Highlights for 12 months ended 31 December 2012

    Highlights for 12 months ended 31 December 2012 •CohortSanofi ocular 2 Dose partnership nearing successful Administration 3 months (UPDRS) conclusion: 6 months (UPDRS) US$53m 1 year (UPDRS) committed to date 2 years (UPDRS) Mean 27%® 1, n=3 • 1x Options exercised forOriginal StarGen™ andMax.UshStat

  4. Slide 4: Our mission…

    Our mission… …is to build a financially self-sustaining company based on the successful development and commercialisation of our LentiVector® platform technology Oxford BioMedica today The future… • Established platform technologies & IP  • Later-stage pipeline • Novel products  • Multiple revenue

  5. Slide 5: Growth strategy

    Growth strategy •CohortTarget high 2 value, fast growing Dose Administration markets such as ophthalmology 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Mean 27% Mean 30% Mean 29% Mean 20% •1, n=3Four potential 1x Original revenue streams: Max. up to 30% Max. up to 50% Max. up to

  6. Slide 6: Product portfolio

    Product portfolio Focused on high value, fast growing markets Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Product Indication Max. up to 30% Stage Max. up to 50% Max. up to 44% Partner Max. up to 3

  7. Slide 7: The ophthalmology opportunity

    The ophthalmology opportunity Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Indication Market1 Main players2 OXB portfolio 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Glaucoma $6.1bn Novartis/Alcon, Pfizer, Max. up to 30% Max. up toMerck 50%

  8. Slide 8: LentiVector platform: ocular portfolio update

    LentiVector® platform: ocular portfolio update •CohortIn June 2012, 2 Dose Sanofi elected Administration to exercise its options 3 months (UPDRS) for StarGen™ 6 months (UPDRS) and UshStat 1 year (UPDRS) ® 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% • Triggered US$3m total

  9. Slide 9: Proprietary manufacturing capabilities

    Proprietary manufacturing capabilities • World leader in the development of lentiviral vector-based products • UK manufacturing facility acquired, refurbished and equipped for £3.6m • 16,000 square feet including 4,400 square feet in cleanrooms • MHRA approval received in June 2012 to enable GMP man

  10. Slide 10: Progress against objectives at FY 2011 (announced 6 March 2012)

    Progress against objectives at FY 2011 (announced 6 March 2012) Objective Cohort2 Dose Administration Guidance Achieved 6 months 3 months 1(UPDRS) Date(UPDRS) Notes 1 year (UPDRS) 2 years (UPDRS) Ocular 1, n=3 portfolio 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Ma

  11. Slide 11: Finance update

    Finance update Tim Watts, Chief Financial Officer © Oxford BioMedica 2013, all rights reserved 11

  12. Slide 12: 2012 financial highlights

    2012 financial highlights1 •CohortRevenue virtually 2 Dose unchanged from 2011, Administration but different 3 months (UPDRS) composition 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Mean 27% Mean 30% 29% Mean 20% •1, n=3R&D spend 1x Original reduced – largely lower Sanofi collaboration Max. up t

  13. Slide 13: Revenue analysis

    Revenue analysis £millions Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Mean 27% Mean 30% Mean 29% Mean 20% 5.0 1, n=3 1x Original Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 4.5 2, n=3 2x Original Mean 28% Mean 34% Mean 29% - Max. up t

  14. Slide 14: R&D

    R&D £millions Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Mean 27% Mean 30% Mean 29% Mean 20% 12.0 1, n=3 1x Original Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 2, n=3 2x Original Mean 28% Mean 34% Mean 29% - 10.0 Max. up to 53% Max.

  15. Slide 15: Cash flow statement & cash position

    Cash flow statement & cash position Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% £n=3 2, millions 2x Original Mean 28% Mean 34% 2012 Mean

  16. Slide 16: Financial outlook

    Financial outlook •CohortSufficient financial 2 Dose resources to fund operations Administration 3 months (UPDRS) into6 months Q1 2014 (UPDRS) on current 1 year (UPDRS) plans 2 years (UPDRS) Mean 27% Mean 30% Mean 29% Mean 20% •1, n=3 1x Excludes potential Original revenue sources such Max. up as: t

  17. Slide 17: Illustrative potential revenue streams

    Illustrative potential revenue streams • Cohort2 “Lumpy” Dose milestonesAdministration from Sanofi and 3 monthsfuture (UPDRS) royalties 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3• ProSavin /TroVax /anti-5T4 antibody (Pfizer) Mean 30% ® ® 1x Original Mean 27% Mean 29% Mean 20% • Develop &

  18. Slide 18: Current objectives/anticipated programme developments

    Current objectives/anticipated programme developments OBJECTIVE Dose Cohort2 Administration 3 months (UPDRS) 6 months (UPDRS) GUIDANCE 1 year (UPDRS) 1 2 years (UPDRS) 1, n=3 Ocular portfolio 1x Original Mean 27% Mean 30% Mean 29% Mean 20% ® Six-month RetinoStat data Max. up to 30% Max. up to 50% H2

  19. Slide 19: Summary: focused on progress

    Summary: focused on progress •CohortDiversifiedDose 2 product portfolio targeting 3high Administration value markets months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Mean 27% Mean 30% Mean 29% Mean 20% •1, n=3Ocular Phase 1x Original I/II collaboration with Sanofi nearing successful Ma

  20. Slide 20: Contact us

    Contact us: Investors: Oxford BioMedica plc Manufacturing facility Lara Mott Medawar Centre Harrow House Head of Corporate Robert Robinson Avenue County Trading Estate Communications The Oxford Science Park Transport Way, Cowley Oxford OX4 4GA Oxford OX4 6LX Tel: +44 (0) 1865 783 000 United Kingdom

Oxford BioMedica — FY2012 Earnings Presentation on 6ix